Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Portfolio Pulse from
A class action lawsuit has been filed against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 01, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging securities fraud, with potential implications for its stock performance and corporate strategy following research program discontinuation.
The lawsuit and sudden research program discontinuation suggest significant operational challenges and potential financial strain, which could negatively impact investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100